Tumor shrinkage and partial responses observed in patients with advanced head and neck squamous cell carcinoma (HNSCC) treated with MCLA-158
In preclinical studies, Zeno observed to block cell growth 100 fold more potently than anti-HER3 antibody alone
Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today presented clinical data on MCLA-158, including clinical responses observed in advanced head and neck squamous cell carcinoma (HNSCC) and preclinical data on zenocutuzumab (Zeno) at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics.
Dr. Andrew Joe, Chief Medical Officer at Merus, said, “We are encouraged by the early evidence of clinical activity of MCLA-158 in patients with advanced, previously treated HNSCC, further validating the potential of our Biclonics® platform. With Zeno, our preclinical research continues to reinforce the mechanisms by which Zeno is capable of potently inhibiting the growth of NRG1 fusion cancers.”
https://finance.yahoo.com/news/merus-presents-early-clinical-data-130000593.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.